Sean Patmore

TL;DR: Evidence suggests that elevated VWF levels in cancer patients may not only contribute to cancer associated coagulopathies but may also mediate cancer progression and metastasis.

TL;DR: The hypothesis that loss of terminal sialylation contributes to the pathophysiology underpinning low VWF in at least a subgroup of patients by promoting enhanced clearance is supported.

TL;DR: The von Willebrand factor (VWF), a haemostatic plasma glycoprotein, has been shown to play an important role in tumour progression and metastasis in breast cancer as discussed by the authors.

TL;DR: Over the last decade, low-molecular-weight heparin has been the preferred anticoagulant agent for patients with cancer-associated thrombosis due to improved efficacy compared with vitamin K antagonists, although limitations for their widespread use remain, with the potential for increased bleeding risk, drug interactions, and poor DOAC metabolism.

TL;DR: In a model of melanoma, treatment with low molecular weight heparin (LMWH) negatively regulated VWF secretion and attenuated tumor metastasis, and elevated plasma VWF levels constitute an independent biomarker for VTE risk.